Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Dopamine reuptake inhibitors in development at Pola for Parkinson's disease

Oct. 20, 1998

New AMPA and NMDA receptor antagonists in early research at RPR

Oct. 20, 1998

Neurotrophic/neuroprotective agents in development at Sanofi

Oct. 20, 1998

Good efficacy, tolerability reported for Almirall Prodesfarma's antimigraine candidate

Oct. 20, 1998

Statins provide protection against stroke via effects on eNOS

Oct. 20, 1998

Novel CNS technology with broad potential application available from BTG

Oct. 20, 1998

Clinical results cast further doubt on the role of substance P in migraine

Oct. 19, 1998

Verapamil recommended for first-line treatment of cluster headache

Oct. 19, 1998

Subtype-selective 5-HT1D agonists developed at MS&D for migraine

Oct. 19, 1998

Lundbeck describes novel class for psychiatric and neurological disorders

Oct. 19, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...